Merck to Acquire Pandion for ~$1.85B
Shots:
- Merck to acquire all outstanding shares of Pandion for $60/share in cash- representing the equity value of ~$1.85B. The transaction is expected to close in H1’21
- The acquisition will strengthen Merck’s portfolio with the addition of candidates targeting a broad range of autoimmune diseases
- Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes along with its lead candidate (PT101) intended to treat UC and other autoimmune diseases
Ref: Businesswire | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com